Citations

Clear

8 citation(s) found for "Tomlinson, Amanda D".

Adding an extension piece to the end of the purge side arm of the Impella device can prevent the incidence of the cassette breaking and decrease the Impella device failure rate: Impact of practice change on patient outcome
SATASHIA, PARTHKUMAR , White, Andrew D. , Isha, Shahin , Hanson, Abby , Jenkins, Anna , Blasavage, Jessica, Matos, Nikki , Tomlinson, Amanda, Zhang, Stephanie , Quiñones, Quintin J., Waldron, Nathan H. , Kiley, Sean , Chaudhury, Sanjay, Shapiro, Anna B, Sanghavi, Devang , White, Andrew , Quinones, Quintin, Waldron, Nathan, Guru, Pramod K , Sanghavi, Devang K., Jenkins, Anna S , Shahin, Isha , White, Andrew, Bhattacharyya, Anirban , Guru, Pramod , Franco, Pablo Moreno

Mayo Clinic

Perfusion | December 7, 2023 | Volume: 39 | Issue: 8 | Pages: 1757-1760

10.1177/02676591231220305 | PMID 38060246 Get It

Background: Impella 5.5® with Smart Assist is a minimally invasive Left Ventricular Assist Devices (LVAD) approved by the Food and Drug Administration (FDA) for treating ongoing cardiogenic shock for up to 14 days. The Impella® intends to reduce ventricular workload and provide the circulatory support necessary for myocardial recovery. Research Question: Compared to standard practice, does adding an extension piece to the purge tube side arm of the Impella® Device decrease the incidence of device failure and positively impact the health outcome of adult patients receiving Impella® support? Study Design and Methods: A retrospective chart review of ICU patients was done at a tertiary care center from August 2018 to August 2022 to assess the differences in patient outcomes related to Impella® Device utilization before and after the implementation of the extension piece to the purge tube sidearm. Among patients reviewed, a total of 20 were included in our review, with seven not having the purge tube side arm extension added, while 13 patients had the extension. Results: The two study groups had no significant difference in patient health outcomes. Additionally, there were no instances of device failure requiring explanation without the extension tubing. However, there were no cases of the purge cassette cracking with the addition of the extension tubing. Conclusion: The addition of extension tubing to the purge cassette of the Impella® Device did not impact patient health outcomes or the incidence of device failure. There was a complete reduction in the incidence of the purge cassette cracking, which could reduce the potential for infection or device failure over a long period of mechanical support. There is a need for long-term prospective studies to confirm the results.
Miller Fisher Syndrome from Asialo-GM1 Antibodies: “How can a Rare Disease Become Rarer?” (P5.315)
Tomlinson, Amanda, Dhakal, Laxmi, Freeman, William D.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.p5.315 Get It

Safety and Tolerability of Concentrated Intraventricular Nicardipine for Poor-Grade Aneurysmal Subarachnoid Hemorrhage–Related Vasospasm
Zahra, Kaneez , Santos, Christan D. , Peacock, Sarah , Jackson, Daniel A., Siegel, Jason , Freeman, William D. , Peacock, Sarah H, Siegel, Jason L, Freeman, William D , Domingo, Ricardo A. , Turnbull, Marion T. , Tawk, Rabih G.

Mayo Clinic

Journal of Personalized Medicine | February 27, 2023 | Volume: 13 | Issue: 3 | Pages: 428

10.3390/jpm13030428 | PMID 36983610 Get It

Objective: To report the preliminary safety, tolerability, and cerebral spinal fluid (CSF) sampling utility of serial injections of concentrated intraventricular nicardipine (IVN) in the treatment of aneurysmal subarachnoid hemorrhage (aSAH). Methods: We report the clinical, radiographic, and laboratory safety and tolerability data of a retrospective case series from a single academic medical center. All patients with aSAH developed vasospasm despite enteral nimodipine and received serial injections of concentrated IVN (2.5 mg/mL). CSF injection safety, tolerability, and utility are defined and reported. Results: A total of 59 doses of concentrated IVN were administered to three patients with poor-grade SAH. In Case 1, a 33-year-old man with modified Fisher scale (mFS) grade 4 and Hunt-Hess scale (HH) score 4 received 26 doses; in Case 2, a 36-year-old woman with mFS grade 4 and HH score 5 received 13 doses; and in Case 3, a 70-year-old woman with mFS grade 3 and HH score 4 received 20 doses. No major safety or tolerability events occurred. Two patients were discharged to a rehabilitation facility, and one died after discharge from the hospital. Conclusions: A concentrated 4 mg IVN dose (2.5 mg/mL) in a 1.6 mL injection appears relatively safe and tolerable and potentially offers a second-line strategy for treating refractory vasospasm in poor-grade SAH without compromising intracranial pressure or cerebral perfusion pressure.
1112: ECMO Rounding: Multidisciplinary Approach
Tomlinson, Amanda, Hannon, Rachel, Sanghavi, Devang , Lykins, Amy , Cushenbery, Kristin, Pham, Si M. , Franco, Pablo Moreno , Guru, Pramod

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 557-557

10.1097/01.ccm.0000730336.05608.0b Get It

399: Cardiac Tamponade Following CT Contrast Injection: A Case Report
Tomlinson, Amanda, Ojard, Michelle, Lykins, Amy , Onweni, Chidinma, McPhearson, Kimm, Rogers, Ashley , Siegel, Jason

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 189-189

10.1097/01.ccm.0000727484.62618.84 Get It

307: COVID-19 Infodemics: How Social Media Shared Information Rapidly to Global Healthcare Teams
Sanghavi, Devang , Tomlinson, Amanda, Rogers, Ashley , Gibson, C. Michael , Brooks, Ian M. , Freeman, William D.

Mayo Clinic

Critical Care Medicine | December 18, 2020 | Volume: 49 | Issue: 1 | Pages: 140-140

10.1097/01.ccm.0000727116.59922.84 Get It

Multimodal Neuromonitoring in Neurocritical Care
Peacock, Sarah , Tomlinson, Amanda, Peacock, Sarah H, Tomlinson, Amanda D

Mayo Clinic

AACN Advanced Critical Care | June 6, 2018 | Volume: 29 | Issue: 2 | Pages: 183-194

10.4037/aacnacc2018632 | PMID 29875115 Get It

Neuromonitoring is important for patients with acute brain injury. The bedside neurologic examination is standard for neurologic monitoring; however, a clinical examination may not reliably detect subtle changes in intracranial physiology. Changes found during neurologic examinations are often late signs. The assessment of multiple physiological variables in real time can provide new clinical insights into treatment decisions. No single monitoring modality is ideal for all patients. Simultaneous assessment of cerebral hemodynamics, oxygenation, and metabolism, such as in multimodal monitoring, allows an innovative approach to individualized patient care.